Gold Standard
Regenerative
A mix of healing cells that works together the way your body naturally heals, sending a broader repair signal than a single cell type can on its own.
Stromal Vascular Fraction (SVF) is a mix of healing cells and signaling molecules taken from stromal tissue. Unlike a single cell type, SVF contains a whole community of cells: stem cells, fat-cell precursors, blood vessel precursors, immune cells, and growth factors. Together they create a complex healing signal.
This variety is a strength. These cell types work together at the same time to reduce inflammation, rebuild blood vessels, regulate the immune system, and repair tissue. Instead of targeting one repair process, SVF activates several at once.
At GSS, "stromal factors" refers to this full preparation: all the healing signals and cell types from stromal tissue, delivered to the area that needs repair.
Both approaches use regenerative biology, but they differ in what cells they contain, how they work, and what conditions they are best suited for.
Because SVF contains many cell types, it can be used for a wide range of conditions.
SVF reduces inflammation inside joints and supports cartilage, tendon, and ligament repair. The mix of stem cells and blood vessel precursors helps both tissue repair and blood flow at the same time.
Certain cell types in SVF help the body reset its metabolic balance. Early evidence suggests SVF may improve insulin sensitivity and support management of metabolic syndrome when used alongside other regenerative treatments.
Blood vessel-forming cells in SVF speed up wound healing by quickly building new blood supply to damaged tissue. This makes it especially helpful for chronic wounds and recovery after surgery.
As we age, our stromal cells naturally decline. SVF can help replenish them, with evidence for improved skin quality, tissue health, and whole-body repair capacity. It is often paired with MSC therapy in longevity protocols.
Not sure whether this applies to your case? Candidacy is determined by medical review of your history and imaging, not by a form. The consultation is complimentary.
See If You QualifyAn outpatient visit where the preparation is processed and given the same day, with minimal recovery time.
The treating provider reviews your health history, any imaging, and your goals. They decide whether SVF, isolated stem cells, exosomes, or a combination is the best fit for you.
For donor-based protocols, we confirm the quality, viability, and cell composition of the preparation before moving forward.
The preparation is concentrated and checked for cell health and composition on the same day it will be administered.
The physician injects the preparation precisely into the target area. Most sessions are outpatient with no general anesthesia needed.
Some soreness at the injection site is normal for 24 to 72 hours. We check in with you at weeks 4, 8, and 12 to track your healing and decide if a second round of treatment is needed.
Stromal vascular fraction, often shortened to SVF, is a mixed cell population separated from adipose tissue. It contains several cell types rather than a single isolated one.
Isolated mesenchymal stem cell preparations aim for a single, characterised cell type. SVF is a mixture, so its composition varies more between preparations. That variability is one reason results across studies are difficult to compare.
It is derived from adipose tissue. How that tissue is collected and processed, and by which laboratory, are reasonable questions to ask any clinic offering it.
No. SVF preparations are not FDA-approved for the uses discussed here, and the FDA has issued guidance on cell-based products marketed in the United States. Procedures here take place in Mexico under COFEPRIS regulation.
A physician, after reviewing your history and imaging. Suitability depends on the individual case rather than the preparation itself.
Request a consultation to find out whether stromal factors, isolated stem cell therapy, or a combination is the right fit for your condition.
See If You Qualify →Medically reviewed by Dr. Karla Chavira, MD, Regenerative Medicine Physician and CEO of CMCells (Cédula Profesional on file).
Last reviewed: July 2026